The list price for Praluent (alirocumab) in the U.S. for 2025 is not yet publicly available. Drug pricing is typically announced closer to the end of the year or at the beginning of the new year.
How much did Praluent cost in previous years?
In 2023, the list price for Praluent in the U.S. was approximately $5,760 per year for the 75 mg every two weeks dosage. The 150 mg every two weeks dosage was approximately $5,760 per year. [1]
How is Praluent priced?
Praluent is administered by injection. The pricing often reflects the dosage and frequency of administration. The list price is the manufacturer's suggested retail price and does not account for discounts or rebates that may be available through insurance or patient assistance programs.
What factors influence Praluent's price?
Drug pricing is influenced by several factors, including research and development costs, manufacturing expenses, marketing, and the perceived value of the drug in treating a specific condition. Market competition also plays a role. [1]
What is Praluent used for?
Praluent is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It is prescribed for adults with very high LDL cholesterol levels, such as those with heterozygous or homozygous familial hypercholesterolemia, or those who have had a recent heart attack or stroke and have high LDL cholesterol despite taking other cholesterol-lowering medications. [1]
Are there alternatives to Praluent?
Other PCSK9 inhibitors are available, such as Repatha (evolocumab). Statins are also a common class of cholesterol-lowering medications. The choice of treatment depends on individual patient needs, medical history, and response to therapy.
When does Praluent's patent expire?
Information on Praluent's patent expiration dates is complex and can involve multiple patents covering different aspects of the drug, including its composition, method of use, and manufacturing. According to DrugPatentWatch.com, Praluent's key patents are expected to expire in the coming years. [2]
Who makes Praluent?
Praluent is jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals. [1]
Sources:
[1] Praluent Official Website
[2] DrugPatentWatch.com